Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sensor measurements

- PMLiVE

Sanofi partners with AI specialist BioMap in deal worth more than $1bn

The strategic collaboration is aimed at accelerating drug discovery for biotherapeutics

- PMLiVE

Differences in immune responses could optimise future COVID-19 vaccines

Vulnerability to different mutations was linked to previous infections and vaccination

- PMLiVE

Moderna’s COVID-19/flu combination vaccine shows promise in phase 1/2 study

The approach could simplify immunisation practices and lead to higher vaccine uptake

- PMLiVE

New vaccine technology could help fight future viruses and variants

The antigen technology could enhance vaccine protection against potential threats

- PMLiVE

Medscape Education’s Large Presence at IDWeek 2023

Medscape are powering education and disease state awareness in infectious diseases at #IDWeek 2023

Medscape Education Global

- PMLiVE

Nobel Prize in Medicine awarded to pair of scientists behind mRNA COVID-19 vaccines

Katalin Karikó and Drew Weissman’s findings paved the way for effective mRNA vaccines

- PMLiVE

ScreenPoint Medical to showcase AI software at European scientific meeting

Trial results show that the software boosts breast cancer detection by 20%

- PMLiVE

Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments

The companies will work together to develop new cardiovascular treatments

- PMLiVE

COVID-19 could be key in identifying viruses with pandemic potential

Researchers analysed major variants of concern, including the Omicron subvariants

- PMLiVE

DeepMind’s AI tool classifies effects of mutations in genetic diseases

The Google unit's AlphaMissense tool has classified the effects of 71 million ‘missense’ mutations

- PMLiVE

Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia

The deals aim to accelerate drug development in oncology, neurology and immunology

- PMLiVE

Moderna’s XBB.1.5-adapted COVID-19 vaccine receives MHRA approval

The vaccine has been updated to target the currently circulating XBB.1.5 Omicron variant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links